Should I buy Stryker Corporation (SYK) stock or is it too late?

Stryker Corporation · Health Care · price $322

See the full Stryker Corporation (SYK) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $369 (+15 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 6 reliable analysts $364+13 %

The 10 other firms $397+23 %

How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $364 median. “The 10 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Stryker Corporation

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
BTIG	93 %	+17.9 %	15	$358 +11%
Wells Fargo	69 %	+16.9 %	16	$418 +30%
Citigroup	67 %	+16.7 %	15	$385 +20%
Piper Sandler	73 %	+12.8 %	11	$390 +21%
JP Morgan	62 %	+12.5 %	8	$350 +9%
RBC Capital	75 %	+9.3 %	16	$420 +30%
Canaccord Genuity	56 %	+8.3 %	16	$400 +24%
Needham	56 %	+2.9 %	9	$418 +30%

In short — Should you invest in Stryker Corporation? Is it too late, still worth it? Analysts are fairly positive (76% buy, median target $388, i.e. +20%), and the most reliable on SYK targets even higher. But the valuation is stretched (P/E ~34). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

76% of analysts rate it a buy (Buy consensus, 17 ratings) — a sign of market conviction.
Median price target $388, i.e. +20% from the current price ($322).
The most reliable firm on SYK, UBS (100% hit rate, 2 scored calls), targets $380 (call made on March 17, 2026, maturing on March 17, 2027) (+18%) in its most recent call, and $400 (call made on February 24, 2026, maturing on February 24, 2027) (+24%) in the one coming due soonest.
5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 17 ratings, 4 are neutral.
High valuation (P/E ~34): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on SYK

Median target $388 (+20%) · 17 ratings · Buy consensus

Strong Buy00%

Buy1376%

Hold424%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Stryker Corporation now?

We won't decide for you. The facts: 76% of analysts rate it a buy, median target $388 (+20%), and UBS (most reliable on SYK, 100%) targets $380. Weigh that against valuation (P/E ~34). This is not personalized advice.

Is it too late to invest in Stryker Corporation?

Not according to analysts: the median target ($388) is still +20% above the current price ($322) (most reliable on SYK: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Stryker Corporation still worth investing in?

It depends on the gap between the price ($322) and its estimated value: analysts target $388 on median (+20%), with 76% buys (most reliable on SYK: UBS, 100%). Cross-check with their real reliability on SYK and the cautions above. Information, not advice.

What's the main risk in buying SYK?

The consensus is not unanimous: of 17 ratings, 4 are neutral.

→ Go deeper: the full Stryker Corporation profile (consensus, analyst reliability, price target, performance).